The research will specifically focus on Mycoplasma hyopneumoniae (M.hyop), the causative agent of the disease, and aim to progress vaccine development.
Zoetis has stumped up another £300K in kind to support the research.
M.hyop is present in 80% of UK pig herds, which can result in a 16% reduction of growth and a 14% reduction in feed conversion in pigs.
This therefore, is not only a welfare issue for pigs but can significantly increase production costs for farmers.
Piglets are at particular risk of contracting the disease alongside secondary pathogens during lactation.
There are currently no commercial vaccines available that would prevent initial infection, and while M.hyop is susceptible to a variety of antibiotics, their use needs to be reduced to avoid overuse and the occurrence of multi-drug resistant strains.
The priority for the RVC researchers will therefore be developing new vaccines.
The team will also research the optimisation of protocols to eliminate M.hyop from pig herds in an effort to further minimise potential transmission.
Professor Dirk Werling, Professor of Molecular Immunology at the RVC, said: “Infection of Mycoplasma hyopneumoniae is a really debilitating disease in pigs that causes huge economic losses for farmers.
"I am very pleased that we will be able to continue working with a pharmaceutical partner to develop a new vaccine using state-of the-art technologies.”
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.